Bisaha J G, Simon T C, Gordon J I, Breslow J L
Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York, New York 10021, USA.
J Biol Chem. 1995 Aug 25;270(34):19979-88. doi: 10.1074/jbc.270.34.19979.
Studies using transgenic mice indicate that expression of the human apolipoprotein (apo) A-I gene in the liver and small intestine is controlled by spatially distinct cis-acting DNA elements; hepatic expression is controlled by a domain defined by nucleotides -256 to -1, while small intestinal expression requires elements positioned 9 kilobases 3' to the gene, between nucleotides -1300 and -200 of the convergently transcribed apoC-III gene. In this report we have mapped this enhancer to a 260-base pair (bp) region of the apoC-III promoter spanning nucleotides -780 to -520. The elements contained within this 260-bp apoC-III domain are sufficient to direct a pattern of expression in villus-associated enterocytes distributed along the duodenal-to-ileal axis that resembles that of mouse and human apoA-I. However, the elements produce inappropriate activation of apoA-I expression in proliferating and nonproliferating crypt epithelial cells, and in subpopulations of cholecystokinin- and serotonin-producing enteroendocrine cells. Cis-acting suppressors of these inappropriate patterns of expression are located outside of nucleotides -1300 to -200 of the human apoC-III gene. DNase I protection and gel mobility gel shift assays identified two 21-bp sequences, nucleotides -745 to -725 and -700 to -680 of human apoC-III, which bind nuclear proteins present in a human enterocyte-like cell line (Caco-2). These sequences are conserved in the orthologous mouse apoC-III gene. The 260-bp apoC-III element is the first intestinal enhancer that has been identified in an in vivo system and should provide insights about how cell lineage-specific, differentiation-dependent, and cephalocaudal patterns of gene expression are established and maintained in the perpetually renewing gut epithelium. In addition, novel intestinal transcription factors may bind to the enhancer and regulate its activity.
利用转基因小鼠进行的研究表明,人载脂蛋白(apo)A-I基因在肝脏和小肠中的表达受空间上不同的顺式作用DNA元件控制;肝脏中的表达由核苷酸-256至-1所界定的区域控制,而小肠中的表达则需要位于该基因3'端9千碱基处、在反向转录的apoC-III基因的核苷酸-1300至-200之间的元件。在本报告中,我们已将该增强子定位至apoC-III启动子的一个260碱基对(bp)区域,该区域跨越核苷酸-780至-520。这个260-bp的apoC-III结构域内所含的元件足以指导沿十二指肠至回肠轴分布的绒毛相关肠上皮细胞中的表达模式,该模式类似于小鼠和人apoA-I的表达模式。然而,这些元件在增殖和非增殖的隐窝上皮细胞以及产生胆囊收缩素和血清素的肠内分泌细胞亚群中会导致apoA-I表达的不适当激活。这些不适当表达模式的顺式作用抑制子位于人apoC-III基因的核苷酸-1300至-200之外。DNase I保护和凝胶迁移凝胶阻滞分析鉴定出两个21-bp序列,即人apoC-III的核苷酸-745至-725和-700至-680,它们与人肠上皮样细胞系(Caco-2)中存在的核蛋白结合。这些序列在直系同源的小鼠apoC-III基因中是保守的。260-bp的apoC-III元件是在体内系统中鉴定出的首个肠道增强子,应能为在不断更新的肠道上皮中如何建立和维持细胞谱系特异性、分化依赖性和头尾模式的基因表达提供见解。此外,新的肠道转录因子可能与该增强子结合并调节其活性。